InsiderTrades

Form 4 for CRSP CRISPR Therapeutics AG

Accepted 2024-02-21 00:00:00 ET · period of report 2024-02-18 · accession 0000950170-24-018175 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-02-21 2024-02-18 CRSP KASINGER JAMES R. GC, Sec M - OptEx — +3,825 59.3K +7% —
D 2024-02-21 2024-02-20 CRSP KASINGER JAMES R. GC, Sec S - Sale+OE $79.67 -1,913 57.4K -3% -$152.4K
D 2024-02-21 2024-02-18 CRSP KASINGER JAMES R. GC, Sec M - OptEx — -3,825 7,650 -33% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Shares 2024-02-18 M A 3,825 — 59,284 D — — (F1) Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. (F2) Includes 615 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.
2 Common Common Shares 2024-02-20 S D 1,913 $79.67 57,371 D — — (F3) Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
3 Derivative Restricted Stock Units 2024-02-18 M D 3,825 — 7,650 D — · — to — 3,825 Common Shares (F1) Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. (F4) This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.